{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:20:10Z","timestamp":1788236410152,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072898"],"award-info":[{"award-number":["82072898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92359201"],"award-info":[{"award-number":["92359201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82072898"],"award-info":[{"award-number":["82072898"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["92359201"],"award-info":[{"award-number":["92359201"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Purpose: To evaluate the pathogenicity of BRCA2 variants of uncertain significance (VUS) located within the functionally critical exons 15\u201326 using published SGE data, and to reclassify these VUS by integrating clinical phenotypes. Methods: A total of 15,092 breast cancer patients were enrolled in this study, among which 457 distinct BRCA2 VUS were identified in 1051 carriers. Based on SGE scores, 88 BRCA2 VUSs within exons 15\u201326 were functionally assessed and carriers reclassified as functionally pathogenic, functionally benign, or remaining VUS. Clinicopathological characteristics were subsequently compared across variant groups. Results: Of these 88 evaluated BRCA2 VUSs (187 carriers), 15 were reclassified as functionally pathogenic (20 carriers), 66 as functionally benign (154 carriers), and 7 remained VUS (13 carriers). Compared with non-carriers, carriers with functionally pathogenic variants exhibited a significantly higher prevalence of a family history of any cancer (65.0% vs. 31.1%, p = 0.002), particularly breast and\/or ovarian cancer (35.0% vs. 10.0%, p = 0.002), as well as a trend toward a higher incidence of bilateral breast cancer (10.0% vs. 2.4%, p = 0.085). In contrast, individuals harboring functionally benign variants demonstrated clinicopathological characteristics similar to non-carriers. Conclusion: SGE-based functional scoring system provides a reliable approach for reclassifying BRCA2 VUS. When integrated with clinical phenotypes, it enhanced the accuracy of pathogenicity assessment.<\/jats:p>","DOI":"10.3390\/curroncol33090521","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:19:26Z","timestamp":1788232766000},"page":"521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reclassification of BRCA2 Variants of Uncertain Significance Using Saturation Genome Editing Combined with Clinical Phenotypes in Breast Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Yueran","family":"Shen","sequence":"first","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Jiuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Li","family":"Hu","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-1371","authenticated-orcid":false,"given":"Jie","family":"Sun","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-8712","authenticated-orcid":false,"given":"Lu","family":"Yao","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"visualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-3839","authenticated-orcid":false,"given":"Ye","family":"Xu","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-8107","authenticated-orcid":false,"given":"Yuntao","family":"Xie","sequence":"additional","affiliation":[{"name":"Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12813","DOI":"10.1038\/ncomms12813","article-title":"A second DNA binding site in human BRCA2 promotes homologous recombination","volume":"7","author":"Martin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature01230","article-title":"Insights into DNA recombination from the structure of a RAD51-BRCA2 complex","volume":"420","author":"Pellegrini","year":"2002","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.molcel.2023.06.031","article-title":"Visualization of direct and diffusion-assisted RAD51 nucleation by full-length human BRCA2 protein","volume":"83","author":"Belan","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-biochem-013118-111058","article-title":"The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination","volume":"88","author":"Zhao","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1038\/s41467-024-52699-3","article-title":"BRCA2 stabilises RAD51 and DMC1 nucleoprotein filaments through a conserved interaction mode","volume":"15","author":"Dunce","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","article-title":"BRCA-mutated breast cancer: The unmet need, challenges and therapeutic benefits of genetic testing","volume":"131","author":"Arun","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-18-0468","article-title":"Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer","volume":"25","author":"Kraya","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"R1023","DOI":"10.1186\/bcr1338","article-title":"A common missense variant in BRCA2 predisposes to early onset breast cancer","volume":"7","author":"Narod","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1158\/1078-0432.CCR-22-0203","article-title":"Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG\/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay","volume":"28","author":"Hu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1200\/JCO.2008.17.8228","article-title":"Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance","volume":"26","author":"Spearman","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41436-018-0052-2","article-title":"The functional impact of variants of uncertain significance in BRCA2","volume":"21","author":"Mesman","year":"2019","journal-title":"Genet. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41431-026-02058-1","article-title":"A prioritization framework for BRCA1\/2 variants of uncertain significance identified by comprehensive genomic profiling","volume":"34","author":"Nakahara","year":"2026","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41436-019-0729-1","article-title":"Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort","volume":"22","author":"Li","year":"2020","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","article-title":"BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance","volume":"26","author":"Eccles","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-024-08349-1","article-title":"Saturation genome editing-based clinical classification of BRCA2 variants","volume":"638","author":"Sahu","year":"2025","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41586-024-08388-8","article-title":"Functional evaluation and clinical classification of BRCA2 variants","volume":"638","author":"Huang","year":"2025","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10689-020-00202-4","article-title":"Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer","volume":"20","author":"Wan","year":"2021","journal-title":"Fam. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","article-title":"Reference sequence (RefSeq) database at NCBI: Current status, taxonomic expansion, and functional annotation","volume":"44","author":"Wright","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Nikol\u00e9nyi, A., Dobi, \u00c1., S\u00e1ntha, D., K\u00f3sz\u00f3, R., Iv\u00e1nyi, M., Horv\u00e1th, E., Enyedi, M.Z., Priskin, K., Cs\u00e1nyi, B., and Pat\u00f3cs, A. (2026). Germline BRCA testing in routine clinical practice: A single-center experience. Pathol. Oncol. Res., 32.","DOI":"10.3389\/pore.2026.1612238"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-019-0117-7","article-title":"Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression","volume":"5","author":"Abubakar","year":"2019","journal-title":"npj Breast Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ijc.31841","article-title":"Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort","volume":"144","author":"Li","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.18632\/aging.102783","article-title":"Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer","volume":"12","author":"Chen","year":"2020","journal-title":"Aging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100628","DOI":"10.1016\/j.crmeth.2023.100628","article-title":"Sequencing-based functional assays for classification of BRCA2 variants in mouse ESCs","volume":"3","author":"Biswas","year":"2023","journal-title":"Cell Rep. Methods"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Stella, S., Vitale, S.R., Massimino, M., Martorana, F., Tornabene, I., Tomarchio, C., Drago, M., Pavone, G., Gorgone, C., and Barone, C. (2024). In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients. Genes, 15.","DOI":"10.3390\/genes15070943"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1016\/j.cell.2024.08.039","article-title":"High-resolution functional mapping of RAD51C by saturation genome editing","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101557","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Shin, J.H., Park, K.S., Kim, Y.G., Jang, M.A., Jang, J.H., and Kim, J.W. (2026). Clinical variant interpretation comparing two saturation genome editing-based functional studies for BRCA2. Front. Genet., 17.","DOI":"10.3389\/fgene.2026.1803717"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1093\/nar\/gkad1222","article-title":"The BRCA2 R2645G variant increases DNA binding and induces hyper-recombination","volume":"52","author":"Petitalot","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajhg.2024.02.002","article-title":"Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain","volume":"111","author":"Hu","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1093\/nar\/gkab308","article-title":"Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance","volume":"49","author":"Lee","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102471","DOI":"10.1016\/j.tranon.2025.102471","article-title":"Characterization and functional analysis of BRCA1 and BRCA2 variants in a cohort of 100 unselected patients undergoing germline screening","volume":"59","author":"Shi","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41419-023-06289-8","article-title":"Characterization of BRCA2 R3052Q variant in mice supports its functional impact as a low-risk variant","volume":"14","author":"Mishra","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41588-024-02039-4","article-title":"Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations","volume":"57","author":"Funk","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ajhg.2025.07.005","article-title":"Saturation mapping of MUTYH variant effects using DNA repair reporters","volume":"112","author":"Hemker","year":"2025","journal-title":"Am. J. Hum. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1038\/s41467-026-71393-0","article-title":"Combining multiplexed assays of variant effect for enhanced BRCA2 variant classification","volume":"17","author":"Hu","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41588-024-01799-3","article-title":"Saturation genome editing of BAP1 functionally classifies somatic and germline variants","volume":"56","author":"Waters","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/s41588-024-01800-z","article-title":"Saturation genome editing maps the functional spectrum of pathogenic VHL alleles","volume":"56","author":"Buckley","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sahu, S., Sullivan, T.L., Mitrophanov, A.Y., Galloux, M., Nousome, D., Southon, E., Caylor, D., Mishra, A.P., Evans, C.N., and Clapp, M.E. (2023). Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants. PLoS Genet., 19.","DOI":"10.1371\/journal.pgen.1010940"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:01:27Z","timestamp":1788235287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090521"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090521","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}